ClinicalTrials.gg
Not yet recruitingNCT07182760Updated Sep 19, 2025

Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia

An observational study in Primary Immune Thrombocytopenic Purpura, Amegakaryocytic Aplasia and Unilineage Myelodysplastic Syndrome ( Megakaryocyte Dysplasia), sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-19.

Primary conditionPurpura, Thrombocytopenic, IdiopathicRegistry: Autoimmune DiseasesReclassifiedWhy we changed it
Registry
Autoimmune Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic, Idiopathic
Why
  1. The study's listed conditions name Purpura, Thrombocytopenic, Idiopathic, a narrower term within Autoimmune Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Assiut University.

Started
2025
with 2 others
Observational
9 of 15
5 open now
Registered
14th of 15
by date

Among the 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University, this one is one of 3 that started in 2025, is one of 9 observational ones, and was the 14th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University, or all of them as a file.
02

Study summary

Investigate prevalence of splenomegally in patients with isolated thrombocytopenia.

Asess effect of splenomegally in clinical picture ,Complication, treatment response and disease outcome To explain possible causes of splenomegally in patients with isolated thrombocytopenia

03

Conditions studied

  • Primary Immune Thrombocytopenic Purpura
  • Amegakaryocytic Aplasia
  • Unilineage Myelodysplastic Syndrome ( Megakaryocyte Dysplasia)
  • Lymphoproliferative Disorder With Secondary ITP
  • Autoimmune Diseases With Secondary ITP
04

In context

Purpura, Thrombocytopenic, Idiopathic Reclassified

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

This study's planned enrollment of 100 is below the median of 122 across 99 observational studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with isolated thrombocytopenia between 18 years to 65years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients more than 18 years admitted with isolated thrombocytopenia due to primary Immune thrombocytopenic purpura amegakaryocytic aplasia Unilineage myelodysplastic syndrome ( megakaryocyte dysplasia) lymphoproliferative disorder with secondary ITP diseases with secondary ITP Willingness to participate in the study Admitted patients or those who follow at hematology outpatients clinic

Exclusion criteria

Exclusion Criteria:

EDTA induced pseudothrombocytopenia satellitism Drug induced thrombocytopenia Heparin induced thrombocytopenia / thrombosis syndrome post transfusion purpura Disseminated intravascular coagulopathy patients less than 18 years old patients with bicytopenia or pancytopenia Pregnancy

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Group 1a patients with isolated thrombocytopenia and splenomegaly

    Group 1b patients with isolated thrombocytopenia without splenomegaly.

  • Group 1b patients with isolated thrombocytopenia without splenomegaly.

    Group 1b patients with isolated thrombocytopenia without splenomegaly.

  • Group 2 healthy volunteers.
07

What researchers measure

Primary outcomes

  1. Investigate prevalence of splenomegally in patients with isolated thrombocytopenia. Asess effect of splenomegally in clinical picture ,Complication, treatment response and disease outcome

    1. How many patients with isolated thrombocytopenia present with splenomegaly 2. Do patients with splenomegaly experience different complications compared to those without splenic enlargement 3. Is there a difference in treatment response between patients presenting with splenomegaly and those without splenic involvement

    Time frame: Baseline

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Achterbergh R, Vermeer HJ, Curtis BR, Porcelijn L, Aster RH, Deenik W, Daemen-Gubbels C. Thrombocytopenia in a nutshell. Lancet. 2012 Feb 25;379(9817):776. doi: 10.1016/S0140-6736(11)61643-7. No abstract available. PubMed 22364760 ↗
  • Arnold J, Ouwehand WH, Smith GA, Cohen H. A young woman with petechiae. Lancet. 1998 Aug 22;352(9128):618. doi: 10.1016/s0140-6736(98)05194-0. No abstract available. PubMed 9746024 ↗
  • LAVY R. THROMBOCYTOPENIC PURPURA DUE TO LUPINUS TERMIS BEAN. J Allergy. 1964 Sep-Oct;35:386-9. doi: 10.1016/0021-8707(64)90065-6. No abstract available. PubMed 14216353 ↗
  • Kam T, Alexander M. Drug-induced immune thrombocytopenia. J Pharm Pract. 2014 Oct;27(5):430-9. doi: 10.1177/0897190014546099. Epub 2014 Aug 17. PubMed 25134884 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for May 2027, 19 months later.

Of 31 observational studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 35. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 19, 2025
StartEst.
Oct 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07182760
Lead sponsor
Assiut University
Responsible party
Karim Ashraf hussein youssef (Resident in Internal Medicine Department in Assiut University Hospitals, Assiut University) — Principal investigator
First posted
Sep 19, 2025
Start date
Oct 2025 (estimated)
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 19, 2025

Study contacts

Karim Ashraf, Resident
Contact
Karimazqal123@gmail.com
+20 ext. 01019954118

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion